Abstract: The invention relates to magnetic particles coated with silica (Si02), whereby the silicate layer is closed and tight and is characterized by having an extremely small thickness on the scale of a few nanometers—hereafter also referred to as a silica nanolayer. This invention also relates to an improved method for producing these silicate-containing magnetic particles that, in comparison to the prior art, lead to a product having a closed silicate layer and thus entail a highly improved purity. In addition, the novel method prevents an uncontrolled formation of aggregates and clusters of silicates on the magnetite surface, thereby having a positive influence on the properties and biological applications cited below. The novel method also enables the depletion of nanoparticulate solid substance particles on the basis of a fractionated centrifugation. The inventive magnetic particles exhibit an optimized magnetization and suspension behavior as well as a very advantageous run-off behavior from plastic surfaces.

Abstract: The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a SADR gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat statin induced adverse drug reactions (SADR), the polynucleotide is selected from the group comprising: SEQ ID 1-35 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for SADR gene polypeptide and with or without the SADR gene promoter sequence.

Abstract: Polyelectrolyte monolayers and multilayers for coating optical signal transducers are disclosed.

Abstract: The present invention relates to the field of prognosis of a proliferative disease in a patient. More specifically, the present invention relates to methods for the identification of the likely outcome of breast cancer in a breast cancer patient. The invention also relates to methods for the identification of the likely outcome of breast cancer in a patient on the basis of the ERBB2 status of the patient and expression levels of immune genes in tumour tissue of said patient.